BPI Polyclonal Antibody
Applications
Predicted Reactivity
| Overview | |
| Catalog # | bs-4292R |
| Product Name | BPI Polyclonal Antibody |
| Applications |
ELISA
IHC-P
IHC-F
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Predicted Reactivity | Human |
| Specifications | |
| Conjugation | Unconjugated |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human BPI |
| Immunogen Range | 141-240/487 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
| Target | |
| Gene ID | 671 |
| Subcellular location | Cytoplasm, Secreted, Cell membrane |
| Synonyms | Bactericidal permeability-increasing protein; bactericidal/permeability-increasing protein; BPI; CAP 57; BPI_HUMAN. |
| Background | The antimicrobial protein Bactericidal Permeability Increasing protein (BPI) is a 55 kDa protein found in the primary granules of polymorhonuclear leukocytes (PMN). The cytotoxicity action of BPI is limited to gram negative bacteria, reflecting the high affinity of BPI for bacterial LPS. Binding of BPI to live bacteria via LPS causes anti-infective activites: 1) cytotoxicity via sequential damage to bacterial outer and inner lipid membranes, 2) neutralization of gram-negative bacterial LPS, 3) opsonization of bacteria to enhance phagocytosis by neutrophils. |
| Application Dilution | |
| ELISA | 1:500-1000 |
| IHC-P | 1:200-400 |
| IHC-F | 1:100-500 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |